P-glycoprotein Inhibition for Optimal Drug Delivery

被引:498
作者
Amin, Md. Lutful [1 ]
机构
[1] Stamford Univ Bangladesh, Dept Pharm, Dhaka, Bangladesh
关键词
P-glycoprotein; drug efflux; bioavailability; drug delivery; drug resistance; P-glycoprotein inhibitor;
D O I
10.4137/DTI.S12519
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
P-glycoprotein (P-gp), an efflux membrane transporter, is widely distributed throughout the body and is responsible for limiting cellular uptake and the distribution of xenobiotics and toxic substances. Hundreds of structurally diverse therapeutic agents are substrates to it and it impedes the absorption, permeability, and retention of the drugs, extruding them out of the cells. It is overexpressed in cancer cells and accountable for obstructing cell internalization of chemotherapeutic agents and for developing transporter mediated resistance by cancer cells during anti-tumor treatments. As it jeopardizes the success of drug delivery and cancer targeting, strategies are being developed to overcome P-gp mediated drug transport. This concise review represents a brief discussion on P-gp mediated drug transport and how it hinders the success of various therapies. Its main focus is on various strategies used to tackle this curb in the field of drug delivery and targeting.
引用
收藏
页码:27 / 34
页数:8
相关论文
共 58 条
[1]   Bioavailability of tobramycin after oral delivery in FVB mice using CRL-1605 copolymer, an inhibitor of P-glycoprotein [J].
Banerjee, SK ;
Jagannath, C ;
Hunter, RL ;
Dasgupta, A .
LIFE SCIENCES, 2000, 67 (16) :2011-2016
[2]   Emerging Significance of Flavonoids as P-Glycoprotein Inhibitors in Cancer Chemotherapy [J].
Bansal, Tripta ;
Jaggi, Manu ;
Khar, Roop K. ;
Talegaonkar, Sushama .
JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, 2009, 12 (01) :46-78
[3]   Anthracycline antibiotics non-covalently incorporated into the block copolymer micelles: In vivo evaluation of anti-cancer activity [J].
Batrakova, EV ;
Dorodnych, TY ;
Klinskii, EY ;
Kliushnenkova, EN ;
Shemchukova, OB ;
Goncharova, ON ;
Arjakov, SA ;
Alakhov, VY ;
Kabanov, AV .
BRITISH JOURNAL OF CANCER, 1996, 74 (10) :1545-1552
[4]  
Batrakova EV, 2001, J PHARMACOL EXP THER, V296, P551
[5]   P-glycoprotein is strongly expressed in the luminal membranes of the endothelium of blood vessels in the brain [J].
Beaulieu, E ;
Demeule, M ;
Ghitescu, L ;
Beliveau, R .
BIOCHEMICAL JOURNAL, 1997, 326 :539-544
[6]   Nanoparticles in cancer therapy and diagnosis [J].
Brigger, I ;
Dubernet, C ;
Couvreur, P .
ADVANCED DRUG DELIVERY REVIEWS, 2002, 54 (05) :631-651
[7]   Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP 1049C) in patients with advanced cancer [J].
Danson, S ;
Ferry, D ;
Alakhov, V ;
Margison, J ;
Kerr, D ;
Jowle, D ;
Brampton, M ;
Halbert, G ;
Ranson, M .
BRITISH JOURNAL OF CANCER, 2004, 90 (11) :2085-2091
[8]   Role of P-glycoprotein-mediated secretion in absorptive drug permeability:: An approach using passive membrane permeability and affinity to P-glycoprotein [J].
Doppenschmitt, S ;
Spahn-Langguth, H ;
Regårdh, CG ;
Langguth, P .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1999, 88 (10) :1067-1072
[9]  
DRORI S, 1995, EUR J BIOCHEM, V228, P1020, DOI 10.1111/j.1432-1033.1995.tb20352.x
[10]   Role of P-glycoprotein in distribution of nelfinavir across the blood-mammary tissue barrier and blood-brain barrier [J].
Edwards, JE ;
Alcorn, J ;
Savolainen, J ;
Anderson, BD ;
McNamara, PJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (04) :1626-1628